Breaking AI & Tech News Analyzed

The LeadSéamas O'Reilly's debut novel "Prestige Drama" presents a brilliant wry comedy set in Derry, where a Hollywood actor disappears while filming a TV series about the Troubles. The novel transcends its intriguing premise to explore how places become defined by historical moments, and how stories about such places often fall into predictable formulas.Multiple Perspectives on Historical TraumaO'Reilly uses the TV series "Dead City" as a starting point to weave through different characters connected to the production. From a stressed scriptwriter to a local historian questioning how to talk about the past while still living it, the novel creates a patchwork portrait of the city. This approach echoes Tommy Orange's "There, There," which used multiple voices to explore Native American lives. Each character speaks directly to the reader, revealing their complex relationship with Derry's history and the Hollywood production that has descended upon the city.Commodification of MemoryThe novel masterfully examines how historical trauma becomes marketable. O'Reilly has a keen eye for absurdities: the artist who once painted Bogside murals now doing lecture tours with a "wee moustache and crucifix earring like a plastic Provo"; the ex-IRA hitman offering services as a "consultant." Those once bound by silence now demonstrate how to make a bottle bomb for the cameras. The locals, facing economic necessity, take work that perpetuates clichés—local painters recreate old murals for film sets, while aspiring actors see the production as their only chance to escape.The Haunting of HistoryThis recreation and commodification of the past creates a kind of haunting. The novel is permeated by different ways in which the dead remain inescapable. Ann-Marie, whose son was shot by a British soldier and whose image now appears on book covers and "bloody tea-towels," delivers one of the novel's most powerful voices: "My heart is small and hard, wind-bleached like seaside beach seats." Her reflection on those who came home safely after her son was killed—"It wasn't their fault and I'll never forgive them"—captures the unfixable contradictions of grief.A New Voice in Irish LiteratureBuilding on his previous memoir "Did Ye Hear Mammy Died?"—described as "heartbreakingly funny"—O'Reilly demonstrates a rare gift for moving between opposing tones. The humor in "Prestige Drama" is skillfully weaponized, allowing him to address subjects we often tiptoe around. His language is gloriously vivid, as when a hungover man wakes up "slowly, like a column of dog food muscling its way out of a tin." While some readers may wish the missing actor thread had more prominence, the novel's true focus is on the ordinary people behind the televised version of events, offering a polyphonic exploration of how history continues to shape the present.

The Shift in Canada's Defence Strategy Canada has announced plans to buy a fleet of early warning planes from Sweden's Saab rather than a competing option from Boeing as it seeks to reduce its reliance on the United States. Details of the Deal Prime Minister Mark Carney said on Wednesday that Canada would opt for Saab's GlobalEye, which is based on Bombardier's Global 6500 jet. Boeing's E-7 Wedgetail plane – which has suffered from delays and cost overruns – had also been in contention. Saab's GlobalEye will be a key resource for the Canadian Armed Forces to detect and deter threats across the Arctic. The Prime Minister pledged in March that Canada would take full responsibility for protecting its vast Arctic territory. The Data Analysis Although Carney did not give details of the fleet size or the cost of a potential contract, military officials had earlier said they were looking to buy six early warning aircraft. The Impact Analysis Philippe Lagasse, associate director of international affairs at Ottawa's Carleton University, said Canada's decision to buy the GlobalEye planes was “an important test case for the Carney government's policy of pivoting away from American military capability”. This decision confirms Canada's relationship with Sweden, a new NATO ally that has also been eager to strengthen its ties to the Canadian military. The Prediction Saab is also in the running to sell Canada some of its Gripen fighters. Still, Lagasse of Carleton University said he expected Canada would ultimately decide to stick with a fleet of F-35 jets rather than splitting the fleet by buying some Saab Gripens.

The USMCA Renegotiation The administration of United States President Donald Trump wants to increase the percentage of regionally produced content in North American-built vehicles to qualify for preferential treatment under the US-Mexico-Canada Agreement (USMCA) on trade to 82 percent, with 50 percent of that value produced in the US. Economic Implications The new proposal emerged amid negotiations to revise the USMCA in Mexico City, with Canada not present at the talks. The shift, if accepted, would be a major break from the current USMCA, which requires that 40 percent of the "core parts" value of North American passenger vehicles be produced in high-wage jurisdictions, effectively the US or Canada. The Data Analysis Canada's gross domestic product (GDP) declined, unexpectedly, at an annualised rate of 0.1 percent in the first quarter, Statistics Canada said on Friday, compared with a downwardly revised contraction of 1 percent in the fourth quarter of last year. The Impact Analysis The Canadian economy has been buffeted by, among other things, tariffs from Trump, who has threatened to annex the country and make it the 51st state of the US. Prime Minister Mark Carney was elected on the platform that he would strengthen and diversify the Canadian economy away from the US. The Prediction "Our forecast for growth to ramp up in H2 and through 2027 depends on a favourable USMCA renegotiation, an early end to the Middle East war, and resumption of normal commerce through the Strait of Hormuz," said Tony Stillo, director of Canada economics at Oxford Economics.

The LeadNew Jersey officials have declared a state of emergency and imposed a curfew in response to intensifying immigration protests that have swept across the state. The measures, announced late Thursday, mark a significant escalation in how authorities are addressing the growing demonstrations that have entered their second week.The Emergency DeclarationGovernor Phil Murphy signed the executive order establishing the curfew, which will run from 9 p.m. to 5 a.m. daily in affected municipalities. The declaration grants state police additional authority to maintain order and restrict assembly during nighttime hours. 'These extraordinary measures are necessary to protect both the protesters and the general public,' stated Murphy during a press conference.The protests, which began as demonstrations against recent federal immigration policies, have evolved into broader expressions of discontent over immigrant rights and treatment. Multiple cities across New Jersey have reported clashes between demonstrators and law enforcement, with property damage and arrests occurring in several locations.The Regional ResponseNew Jersey's action follows similar measures taken by neighboring states, including New York and Connecticut, which have also implemented heightened security protocols. The tri-state coordination represents a unified approach to managing what officials describe as 'unprecedented civil unrest' related to immigration issues.Immigrant advocacy groups have criticized the curfew as an infringement on constitutional rights. 'Peaceful assembly is a fundamental American right,' said Maria Rodriguez, spokesperson for the New Jersey Immigrant Coalition. 'This curfew disproportionately targets immigrant communities and will only escalate tensions rather than address the root causes of the protests.'The Economic ImpactThe ongoing demonstrations and subsequent curfew have begun to affect local economies, particularly in areas with high concentrations of immigrant-owned businesses. Several restaurants, retail shops, and service providers have reported reduced customer traffic and have adjusted their operating hours to comply with the curfew.Local chambers of commerce estimate that businesses in affected areas could lose millions of dollars in revenue during the duration of the emergency measures. Tourism officials are also concerned about potential long-term impacts on New Jersey's reputation as a welcoming destination.The Political FalloutThe curfew has quickly become a political flashpoint, with state legislators already planning hearings to examine the governor's emergency powers. Republican lawmakers have accused Murphy of overreach, while Democratic allies have expressed support for maintaining public safety.Nationally, the situation in New Jersey has drawn attention from both major parties, with immigration advocates and opponents alike using the events to advance their respective narratives. The Biden administration has issued a statement calling for 'calm and dialogue' while acknowledging the 'legitimate concerns' of protesters.The Path ForwardLegal experts anticipate that the curfew will face immediate legal challenges, with civil liberties organizations preparing to file injunctions. Constitutional law professor Jennifer Williams noted that 'while states have broad emergency powers, restrictions on assembly during nighttime hours have historically been subject to strict scrutiny by courts.'As the situation continues to develop, community leaders are calling for dialogue between protesters and officials to address the underlying issues driving the demonstrations. The coming days will likely determine whether the curfew successfully de-escalates tensions or further polarizes an already divided state.

Bipartisan Push to Strip Section 224 from the 2026 NDAADemocratic Ro Khanna and Republican Thomas Massie have announced a joint amendment to delete Section 224, a clause that would create an “executive agent” to synchronize U.S. and Israeli defense‑technology programs. Their collaboration marks an unusual alliance between a progressive and a libertarian as they confront a provision many see as a backdoor to deeper military integration.What Section 224 Would Have MandatedThe provision requires the Secretary of Defense to designate an executive agent responsible for “synchronising cooperative efforts” between the United States and Israel, covering research, development, testing, evaluation, integration and industrial cooperation on defence technology.Creates a permanent liaison office within the Pentagon.Oversees joint AI‑driven surveillance, anti‑drone and anti‑tunnel projects.Blurs the line between foreign aid and joint R&D, potentially masking the cost of U.S. support.Financial Scale and Public SentimentThe 2026 National Defense Authorization Act totals roughly $1.15 trillion. While the bill contains a broader “Matters relating to Israel” section, Section 224 is singled out for its technology‑focused language.Recent polling by The New York Times and Siena College shows 57 % of U.S. voters oppose additional economic and military aid to Israel, and 62 % disapprove of the Israeli‑Palestinian conflict overall. The war in Gaza has already claimed more than 75,000 lives, fueling a historic low in American support for Israel.Political Ramifications for US‑Israel Defense TiesThe bipartisan effort underscores a growing willingness to question the “unconditional” nature of U.S. support. While some Republicans, such as Derrick Van Orden, label criticism of the measure as anti‑Semitic, others argue that the technology partnership could entangle U.S. forces in conflicts where Israeli tactics—such as the 2024 pager‑rigging incident—have caused civilian casualties.Khanna’s amendment also revives a broader anti‑war coalition that previously pushed for the release of Jeffrey Epstein files, indicating a strategic use of defense‑budget oversight to advance transparency and limit overseas entanglements.Outlook: What Happens Next in the Legislative ProcessIf the House Armed Services Committee adopts the amendment, the provision will face a floor vote where party leadership is expected to defend the broader Israel‑friendly provisions of the NDAA. However, the public backlash and the rare bipartisan front could force leadership to negotiate a compromise, possibly reshaping how future defence aid is structured—shifting from direct aid to more transparent, project‑based collaborations.Stakeholders to watch include the Pentagon’s Office of the Secretary of Defense, Israeli defence ministries, and advocacy groups on both sides of the aid debate. The next key dates are the committee markup scheduled for early June and the full House vote slated for late July.

The End of an Era: Arne Slot's Departure from Liverpool Inevitable and necessary. Despite the continual briefings coming out of the UK side of the club’s operation, the silence from Liverpool’s American ownership was deafening. No vote of confidence, no contract extension talks and – most significant – no official appointment of Etiënne Reijnen to Arne Slot’s coaching staff. The Event Details: Slot's Sacking Eventually, on Saturday lunctime, six days after the final game of a season in which the Reds lost 19 games, Slot was gone. Regardless of what happens next, it was the correct decision. If the next guy does not do well, that does not mean sacking Slot was a mistake. It made no sense for Liverpool’s ownership to allow this to continue, regardless of how much Michael Edwards and Richard Hughes reportedly wanted to stick with the status quo. The Data Analysis: A Disappointing Season 19 losses in a single season Lack of identity in the team's play Disappointing results and performances The Impact Analysis: A United Fanbase I can’t remember Liverpool fans being more united in wanting a trophy-winning manager removed. Usually there’s a split in the fanbase and it can get quite ugly but this time it was pretty unanimous. We all knew. Some may have half-heartedly railed against the idea of “sacking a league-winning manager” but when it happened there was very little condemnation. Mostly it was relief. The Prediction: A New Era for Liverpool The dream is that our real dad (Klopp) comes home but it’s probably going to be another stepdad – this time a fun Spanish one. Andoni Iraola ticks plenty of boxes, but not all of them. He hasn’t experienced the goldfish bowl of a big club like Liverpool, he hasn’t had to navigate the demands of playing twice, or three times, a week and teams don’t set up against Bournemouth in the same way they do Liverpool.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Collapse of the FavoritesDefending champion Coco Gauff has been dramatically dethroned at the French Open by Anastasia Potapova, while world number one Aryna Sabalenka has solidified her status as a top contender by reaching the fourth round. The day marked a brutal two days for high-ranked players, following the exits of Jannik Sinner and Novak Djokovic, signaling a potential shift in the balance of power at Roland Garros.Gauff's Struggle on the Red ClayGauff was unable to find her best level on Court Philippe Chatrier, losing 4-6, 7-6(1), 6-4. Despite competing hard, the American struggled to capitalize on crucial points. Anastasia Potapova proved decisive with powerful baseline hitting, breaking to love in the opening game and rattling Gauff with aggressive play. The match was marked by a moment of physical struggle for Gauff, who slipped and fell while reaching a ball, though she recovered to win the next two games before ultimately falling in three sets.Sabalenka's Historic 100th WinIn a contrasting performance, Aryna Sabalenka dispatched Daria Kasatkina 6-0, 7-5 on Court Suzanne Lenglen. This victory was significant not only for the scoreline but for the history books; it marked Sabalenka's 100th win as the world number one, making her only the ninth player in WTA history to achieve this feat. She joins an elite list that includes Martina Navratilova, Steffi Graf, Chris Evert, Serena Williams, Martina Hingis, Monica Seles, Justine Henin, and Iga Swiatek.The New Contenders for the TitleGauff's premature exit leaves Iga Swiatek and Sabalenka as the primary contenders to win the Suzanne Lenglen Cup. Meanwhile, Potapova has emerged as a dangerous dark horse after dishing out a significant upset. The tournament's landscape has shifted dramatically, with the path to the final now seemingly open for the remaining top seeds.Future Outlook: The Swiatek-Sabalenka ShowdownWith the heavy hitters falling, the French Open is shaping up to be a battle between the top two women's players. The focus will now turn to whether Sabalenka can maintain her momentum and whether Swiatek can capitalize on the opportunities presented by the exits of the defending champion and other favorites. Potapova's aggressive style poses a unique challenge for anyone remaining in the draw.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."